Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
anti-CTLA-4
anti-PD1
disease control
immune checkpoint inhibitor
immunotherapy
melanoma
re-induction
rechallenge
response
retreatment
safety
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jul 2023
10 Jul 2023
Historique:
received:
24
04
2023
revised:
07
06
2023
accepted:
29
06
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature. In this retrospective multicenter national real-life study, we enrolled patients who had been rechallenged with an ICI after achieving disease control with a first course of ICI, which was subsequently interrupted. The primary objective was to evaluate tumor response, while the secondary objectives included assessing the safety profile, identifying factors associated with tumor response, and evaluating survival outcomes. A total of 85 patients from 12 centers were included in the study. These patients had advanced (unresectable stage III or stage IV) melanoma that had been previously treated and controlled with a first course of ICI before undergoing rechallenge with ICI. The rechallenge treatments consisted of pembrolizumab ( Rechallenging advanced melanoma patients with ICI after previous disease control induced by these inhibitors resulted in high response rates (54%) and disease control (75%). Therefore, ICI rechallenge should be considered as a relevant therapeutic option.
Sections du résumé
BACKGROUND
BACKGROUND
The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature.
PATIENTS AND METHODS
METHODS
In this retrospective multicenter national real-life study, we enrolled patients who had been rechallenged with an ICI after achieving disease control with a first course of ICI, which was subsequently interrupted. The primary objective was to evaluate tumor response, while the secondary objectives included assessing the safety profile, identifying factors associated with tumor response, and evaluating survival outcomes.
RESULTS
RESULTS
A total of 85 patients from 12 centers were included in the study. These patients had advanced (unresectable stage III or stage IV) melanoma that had been previously treated and controlled with a first course of ICI before undergoing rechallenge with ICI. The rechallenge treatments consisted of pembrolizumab (
CONCLUSION
CONCLUSIONS
Rechallenging advanced melanoma patients with ICI after previous disease control induced by these inhibitors resulted in high response rates (54%) and disease control (75%). Therefore, ICI rechallenge should be considered as a relevant therapeutic option.
Identifiants
pubmed: 37509227
pii: cancers15143564
doi: 10.3390/cancers15143564
pmc: PMC10377277
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Cancer. 2021 Sep;155:268-280
pubmed: 34392069
Eur J Cancer. 2017 Apr;75:47-55
pubmed: 28214657
Br J Cancer. 2014 Apr 2;110(7):1721-6
pubmed: 24619072
J Clin Oncol. 2018 Feb 1;36(4):383-390
pubmed: 28671856
Cancers (Basel). 2021 Jun 20;13(12):
pubmed: 34203061
Clin Transl Oncol. 2021 Sep;23(9):1885-1904
pubmed: 33877531
J Immunother Cancer. 2019 Nov 15;7(1):306
pubmed: 31730012
J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521
pubmed: 30539281
Clin Cancer Res. 2013 Apr 15;19(8):2232-9
pubmed: 23444228
J Dtsch Dermatol Ges. 2020 May;18(5):429-436
pubmed: 32311829
Biomedicines. 2022 Dec 29;11(1):
pubmed: 36672591
JAMA Dermatol. 2020 Sep 1;156(9):982-986
pubmed: 32667663
J Clin Oncol. 2020 May 20;38(15):1655-1663
pubmed: 32053428
Future Oncol. 2020 Jul;16(20):1441-1453
pubmed: 32410465
Ann Oncol. 2014 Nov;25(11):2277-2284
pubmed: 25210016
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33500258
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Ann Oncol. 2020 Nov;31(11):1435-1448
pubmed: 32763453
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Bull Cancer. 2020 Nov;107(11):1098-1107
pubmed: 33032816
Cancer Immunol Immunother. 2017 Jan;66(1):113-117
pubmed: 27838762
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32532839
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86
pubmed: 27141885
J Am Acad Dermatol. 2020 Mar;82(3):770-772
pubmed: 31734192
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120803
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Immunother Cancer. 2022 Jun;10(6):
pubmed: 35688555
J Am Acad Dermatol. 2022 Feb;86(2):345-352
pubmed: 34153388
Ann Oncol. 2018 Jan 1;29(1):250-255
pubmed: 29045547
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Nat Rev Clin Oncol. 2020 Nov;17(11):707-715
pubmed: 32636502
Ann Oncol. 2019 Jul 1;30(7):1154-1161
pubmed: 30923820
J Clin Oncol. 2018 Jun 10;36(17):1668-1674
pubmed: 29283791
Int J Cancer. 2022 Jan 15;150(2):317-326
pubmed: 34520567